Latest Safety News

Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.

AKORA Resources has secured a 25-year mining permit for its high-grade Bekisopa iron ore project in Madagascar, marking a pivotal step from exploration to development and unlocking new financing and partnership opportunities.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Life360 has delivered a landmark 2025 with record user growth, revenue, and profitability, driven by its expanding subscription base and new advertising ventures. The company’s transition to an AI-first platform and strategic acquisitions set the stage for ambitious growth in 2026.

Omega Oil and Gas has locked in Helmerich & Payne’s FlexRig® 648 to power an expanded 2026/27 drilling campaign in Queensland’s Taroom Trough, aiming to unlock a vast unconventional oil and gas resource.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

ABx Group’s maiden mixed rare earth carbonate from Tasmania’s Deep Leads resource has been confirmed radiologically safe by ANSTO, with a second, higher-grade sample expected soon. The development could open doors to key international customers and reduce regulatory complexities.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

TerraCom Limited reported a significant half-year loss amid falling coal prices and production challenges, completing a $56 million capital raise to strengthen its financial position.

DTI Group Ltd reported a 33% revenue increase to $5.69 million for the half-year ending December 2025, significantly narrowing its net loss while winning major contracts with Rio Tinto and CAF. The company’s strategic re-entry into Europe and a robust $175 million opportunity pipeline signal a promising outlook.